Merck Begins Phase 3 Trial for LAGEVRIO in High-Risk COVID-19 Patients

Merck, known as MSD outside of the U.S. and Canada, has announced the initiation of the Phase 3 MOVe-NOW clinical trial to further investigate the potential of its oral antiviral COVID-19 treatment, LAGEVRIO™ (molnupiravir). This trial is designed to assess the drug's effectiveness in adults at high risk of severe disease progression, such as those with underlying health conditions or older age. The study will specifically focus on individuals who are symptomatic, have tested positive for COVID-19 within the last four days, and are not currently hospitalized. Additionally, the trial targets patients who cannot use the alternative antiviral treatment nirmatrelvir/ritonavir due to reasons like drug interactions or allergies.

The MOVe-NOW study will test a new formulation of LAGEVRIO, using two smaller 400-mg tablets per dose instead of the original four 200-mg capsules. This version of the medication has not yet been approved anywhere and is part of ongoing efforts to refine and improve treatment options for those suffering from COVID-19. Merck's commitment to finding solutions for high-risk patients is reflected in their aim to address those who might not benefit from other antiviral therapies due to safety concerns or accessibility issues.

Dr. Paula Annunziato, Merck’s senior vice president for infectious diseases, emphasised the urgency of these clinical trials, noting that COVID-19 remains a leading cause of hospitalisation and death. With millions already treated worldwide, LAGEVRIO has been authorised for use in various countries, including the United States under emergency use authorisation, Japan, and Australia. As the pandemic continues to impact global health, Merck hopes the study will provide important data on how LAGEVRIO can help prevent severe outcomes in vulnerable populations.